Current and prior SLE specific medication use at the time of non-lesional skin biopsy
| C5b-9 positive (n=6) | C5b-9 negative (n=10) | P value | |
| Current medications, N (%) | |||
| Hydroxychloroquine | 5 (83) | 9 (90) | 0.63 |
| Glucocorticoid steroids | 6 (100) | 6 (60) | 0.23 |
| Prednisone >40 mg* | 2 (33) | 3 (30) | 0.17 |
| Mycophenolate mofetil† | 3 (50) | 4 (40) | 0.55 |
| Mycophenolate mofetil >2 g | 1 (17) | 1 (10) | 0.89 |
| Calcineurin inhibitor | 1 (17) | 2 (20) | 0.69 |
| Belimumab | 1 (17) | 1 (10) | 0.89 |
| Ravulizumab | 0 | 1 (10) | 0.63 |
| Other‡ | 2 (33) | 1 (10) | 0.60 |
| Prior medications | |||
| Belimumab | 0 | 1 (10) | 0.56 |
| Rituximab | 1 (17) | 3 (30) | 0.56 |
| Glucocorticoid steroids | 6 (100) | 4 (40) | 0.23 |
| Cyclophosphamide | 1 (17) | 5 (50) | 0.31 |
| Azathioprine | 2 (33) | 4 (40) | 0.61 |
| Mycophenolate mofetil† | 1 (17) | 6 (60) | 0.15 |
| Calcineurin inhibitor | 1 (17) | 1 (10) | 0.62 |
*Prednisone equivalent dosing.
†Includes mycophenolic acid.
‡Azathioprine or methotrexate.